Leukemias, lymphomas, and other hematologic cancers:

Indications for ASPARLAS:

Treatment of acute lymphoblastic leukemia as a component of a multi-agent chemotherapeutic regimen.

Adults and Children:

<1month: not established. 1month–21yrs: Give by IV infusion over 1hr. 2500 Units/m2 no more frequently than every 21 days. Dose modifications: see full labeling.

Contraindications:

History of serious thrombosis, pancreatitis, or hemorrhagic events with prior L-asparaginase therapy. Severe hepatic impairment.

Warnings/Precautions:

Have resuscitation equipment available and observe patient for 1hr post-dose. Assess serum amylase and/or lipase levels. Discontinue if serious hypersensitivity reactions, thrombotic events, or pancreatitis occur. Evaluate for hemorrhage with coagulation parameters. Evaluate LFTs at least weekly, during and for ≥6 weeks after last dose. Discontinue and treat if hepatotoxicity occurs. Pregnancy: avoid; exclude status prior to initiation. Advise females of reproductive potential to use effective non-oral contraception (including barrier method) during and for ≥3 months after last dose. Nursing mothers: not recommended (during and for 3 months after last dose).

Pharmacologic Class:

Asparagine-specific enzyme.

Interactions:

Avoid concomitant oral contraceptives.

Adverse Reactions:

Elevated transaminases, increased bilirubin, pancreatitis, abnormal clotting, diarrhea, hypersensitivity, embolic/thrombotic events, sepsis, dyspnea, hemorrhages.

Generic Availability:

NO

How Supplied:

Single-dose vial (5mL)—1

Pricing for ASPARLAS

5ml of 3750 units vial (Qty: 1)
Appx. price $4757
GoodRx